Related by context. Frequent words. (Click for all words.) 74 Patient Enrollment 74 Drug Candidate 72 Generic Version 72 FDA Accepts 71 Commercialization Agreement 71 Completes Enrollment 70 Phase III Trial 70 Exclusive License 70 Clinical Trial Results 70 Inc Therapeutic Competitors 70 Pivotal Phase III 70 Presents Positive 70 Patent Covering 69 BioDelivery Sciences 69 Phase III Clinical Trial 69 Initiate Phase 68 FDA Clears 68 Transcept Pharmaceuticals 68 Cholesterol Drug 68 #.#/Share [002] 68 Announces Initiation 68 Preclinical Data 67 Q1 Loss Narrows 67 Anika Therapeutics 67 RNAi Therapeutics 67 Pivotal Phase 67 4Q Loss Widens 67 Positive Opinion 66 Small Molecule 66 Q3 Loss Narrows 66 Q2 Loss Narrows 66 Initiates Phase 66 Recombinant Human 66 Q2 Loss Widens 66 Metabasis Therapeutics 66 Metastatic Melanoma 66 FDA Clearance 66 Q4 Loss Widens 66 Sunesis Pharmaceuticals 66 FDA Orphan Drug 65 Thrombin 65 Pulmonary Arterial Hypertension 65 Q3 Loss Widens 65 FY# Guidance 65 Low Dose 65 Well Tolerated 65 Eltrombopag 65 Q1 Loss Widens 65 Cyclacel Pharmaceuticals 65 Explore Strategic Alternatives 65 Orphan Drug Status 65 Licensing Deal 65 Exercises Option 64 Pivotal Trial 64 Completes Tender Offer 64 AUXL 64 ACADIA Pharmaceuticals 64 Files Shelf Registration Statement 64 Patent Lawsuit 64 Patent Infringement Lawsuit 64 Patent Infringement Case 64 BPAX 64 Posts Wider Loss 64 Paladin Labs 64 Study Demonstrates 64 Emisphere Technologies 64 XTL Biopharmaceuticals Ltd. 64 Monoclonal Antibody 64 Epratuzumab 64 Receives Patent 64 Patent Issued 63 CYTR 63 Achieves Milestone 63 Idera Pharmaceuticals 63 Aliskiren 63 Licensing Agreements 63 Inc. Nasdaq IMGN 63 Significantly Reduces 63 Barrier Therapeutics Inc. 63 Previously Announced 63 ENZN 63 Blood Thinner 63 Somaxon Pharmaceuticals 63 Prostate Cancer Patients 63 NASDAQ LGND 63 DepoMed 63 Extends Tender Offer 63 Acquires Exclusive 63 Revenues Decline 63 IMMU 63 Chronic Hepatitis C 63 Cervical Cancer Vaccine 63 Smallpox Vaccine 63 Private Placement Offering 63 Genelabs Technologies Inc. 63 Receives FDA Clearance 62 ONTAK 62 Extended Release 62 Shareholder Lawsuit 62 DYAX 62 Reaffirms Guidance